FDA Panel to Weigh Limited Data on Combo for Healthcare-Acquired Pneumonia

(MedPage Today) -- Data from small trials will determine whether an FDA advisory panel recommends the agency approve sulbactam‐durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by Acinetobacter...
Source: MedPage Today Public Health - Category: American Health Source Type: news